SCHEMBL6325829

SCHEMBL6325829

Cc1ccc(S(=O)(=O)N(CCN(C)C)c2ccc(NC(=C3C(=O)Nc4ccccc43)c3ccccc3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
LMNA P02545 4/20 0.42
GAA P10253 2/20 0.42
HTT P42858 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.39
ATM Q13315 1/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
RORC P51449 1/20 0.38
HPGD P15428 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
ALDH1A1 P00352 2/20 0.37
PTGES O14684 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
ALOX5 P09917 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6325827 1.00 MAPT (0.44) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6318782 0.95 L3MBTL1 (0.38) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6318774 0.95 L3MBTL1 (0.38) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6321701 0.89 MAPT (0.37) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6321699 0.89 MAPT (0.37) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6318916 0.88 MAPT (0.44) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL6321330 0.88 MAPT (0.44) MAPTLMNAGAAHTTSMN1; SMN2
SCHEMBL436205 0.87 KMT2A (0.35) MAPTLMNAGAASMN1; SMN2KMT2A
SCHEMBL436206 0.87 KMT2A (0.35) MAPTLMNAGAASMN1; SMN2KMT2A
SCHEMBL6321230 0.87 IDO1 (0.36) MAPTGAAKMT2AALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 MAPT 3817/4885LMNA 2720/4885GAA 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.